Physician profile
Habib M Bashoura
NPI 1730170887
$755.42
in general payments reported to CMS, 2019-2025
23 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $51.27 · 2021: $102 · 2022: $12.92 · 2023: $113 · 2024: $175 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $421.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $72.30 | 2019-2020 | |
| Lilly USA, LLC | $63.54 | 2023-2024 | Zepbound, Jardiance, Mounjaro |
| Abbvie INC. | $58.00 | 2020-2025 | Vraylar |
| Amgen INC. | $57.76 | 2019-2023 | Repatha |
| Avanir Pharmaceuticals, INC. | $53.72 | 2019 | |
| Madrigal Pharmaceuticals | $49.52 | 2025 | Rezdiffra |
| Amarin Pharma, INC. | $40.86 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $39.60 | 2024-2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $35.25 | 2024-2025 | |
| Insulet Corporation | $33.91 | 2024 | Omnipod |
| Alvogen INC | $28.08 | 2023 | Teriparatide |
| Radius Health, INC. | $25.79 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.71 | 2021 | |
| Corcept Therapeutics | $21.48 | 2025 | Korlym |
| Amphastar Pharmaceuticals, INC. | $20.54 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $18.54 | 2021 | |
| Medtronic, INC. | $17.65 | 2023 | Accurian |
| Abbott Laboratories | $16.86 | 2021 | |
| Recordati_rare_diseases_inc. | $16.46 | 2024 | Isturisa, Signifor Lar |
| Merck Sharp & Dohme LLC | $16.26 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.58 | 2019 | |
| Horizon Therapeutics Plc | $15.09 | 2023 | Tepezza |
| Pfizer INC. | $12.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Habib Bashoura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.